Advanced Lung Cancer Inflammation Index as a Predictor of Coronary Slow Flow Phenomenon in Patients with Angina and Non-Obstructive Coronary Arteries

晚期肺癌炎症指数作为心绞痛和非阻塞性冠状动脉患者冠状动脉慢血流现象的预测指标

阅读:1

Abstract

BACKGROUND: The advanced lung cancer inflammation index (ALI) is associated with the prognosis of cardiovascular diseases. However, the relationship between ALI and the occurrence of coronary slow flow phenomenon (CSFP) remains unclear. METHODS: We consecutively enrolled 1495 patients with angina and non-obstructive coronary arteries (ANOCA). In total, 93 patients were diagnosed with CSFP. A 1:2 age- and sex-matched patient with a normal coronary blood flow was selected as the control group. Demographic characteristics, laboratory parameters, and angiographic findings were compared between groups. Univariate and multivariate logistic regression analyses were performed to identify the independent predictors of CSFP in patients with ANOCA. RESULTS: A total of 93 individuals developed CSFP, accounting for 6.4% of the ANOCA patients. Compared with controls, patients with CSFP had a lower body mass index (BMI) and a higher incidence of nitrates before admission (P<0.05). The neutrophil count, neutrophil-to-lymphocyte ratio (NLR), and fasting blood glucose (FBG) level were significantly higher in patients with CSFP, whereas decreased lymphocyte count, albumin level, and ALI were found in patients with CSFP. Multivariable logistic regression analyses revealed that ALI was an independent predictor of CSFP. The receiver operating characteristic (ROC) curve showed that when ALI was ≤389.5, the specificity and sensitivity were 0.624 and 0.652, respectively (AUC, 0.694; 95% CI, 0.633-0.755, P<0.001). Moreover, ALI demonstrated a better predictive value than indicators alone, including albumin level, BMI, and NLR. CONCLUSION: A lower ALI demonstrated a reliable predictive value for the occurrence of CSFP in patients with ANOCA. As an easily calculated and acquired parameter, ALI can be used for risk stratification and optimal management of patients with ANOCA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。